NMTC
NeuroOne Medical Technologies Corporation
NMTC offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over NMTC overall, supported by stronger fundamentals and lower modeled downside.
NMTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NMTC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NMTC PE Valuation
NMTC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NMTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NMTC's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NMTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.04 | -$0.14 |
| Q1 2026 | -$0.94 | +$0.38 |
| Q4 2025 | -$1.08 | +$0.48 |
| Q3 2025 | -$0.54 | +$2.22 |
| Q2 2025 | -$0.90 | +$1.98 |
| Q1 2025 | -$1.32 | +$2.16 |
| Q4 2024 | -$1.56 | +$2.52 |
| Q3 2024 | -$2.76 | +$1.14 |
NMTC is still losing money, but far less than before: $1.04 per share over the past year, against $17.46 at its worst in mid-2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NMTC on earnings quality, reporting a profit while its opponent remains loss making.
NMTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2M | +16% |
| Q1 2026 | $1.9M | +34% |
| Q4 2025 | $2.9M | -12% |
| Q3 2025 | $2.7M | +907% |
| Q2 2025 | $1.7M | +105% |
| Q1 2025 | $1.4M | +0.7% |
| Q4 2024 | $3.3M | +235% |
| Q3 2024 | $272.3K | -63% |
NMTC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -123% | -12 points |
| Q1 2026 | -129% | +65 points |
| Q4 2025 | -59% | -111 points |
| Q3 2025 | -50% | +985 points |
| Q2 2025 | -111% | +227 points |
| Q1 2025 | -193% | +16 points |
| Q4 2024 | 52% | +399 points |
| Q3 2024 | -1034% | -608 points |
NMTC's operating margin was −123% last quarter, down 12 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NMTC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NMTC on profitability, with a higher operating margin.
NMTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.4M | -$1.3M |
| Q4 2025 | -$3.2M | -1617% |
| Q3 2025 | -$1.5M | +$1.2M |
| Q1 2025 | -$56.1K | +$2.2M |
| Q4 2024 | $208K | +$4.1M |
| Q3 2024 | -$2.7M | +$256.7K |
| Q2 2024 | -$2.4M | +$704.3K |
| Q1 2024 | -$2.2M | +$1.5M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with NMTC at up 8.9%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NMTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +255K shares |
| 1 year | +69% | +3.6M shares |
| 3 years | +223% | +6M shares |
| 5 years | +868% | +7.8M shares |
| Available history | +1227% | +8.1M shares |
NMTC has 9M diluted shares, up 69% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over NMTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NMTC Net Leverage
NMTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NMTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 3.3 | Oversold |
NMTC's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NMTC PE vs Healthcare Sector
NMTC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NMTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 25% below |
| 20 week MA | $1.59 | 53% below |
| 50 week MA | $3.28 | 77% below |
| 100 week MA | $4.09 | 82% below |
| 200 week MA | $5.51 | 86% below |
NMTC is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NMTC on trend strength, trading above more of its moving averages.
NMTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $27.5 | -32% |
| 2021 | $27.5 | $13.2 | -52% |
| 2022 | $13.2 | $9.24 | -30% |
| 2023 | $9.24 | $9.48 | +2.6% |
| 2024 | $9.48 | $4.91 | -48% |
| 2025 | $4.91 | $4.38 | -11% |
| 2026 YTD | $4.38 | $0.75 | -83% |
NMTC has finished lower in five of the last six years. It's down 83% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NMTC on returns for 2026, with the stronger performance.